CAS 901119-35-5

Fostamatinib

Description:

Fostamatinib is an oral medication primarily used as a treatment for certain autoimmune conditions, particularly chronic immune thrombocytopenia (ITP). It functions as a spleen tyrosine kinase (SYK) inhibitor, which plays a crucial role in the signaling pathways of immune cells. By inhibiting SYK, Fostamatinib helps modulate the immune response, reducing platelet destruction in ITP patients. The substance is characterized by its molecular formula, which reflects its complex structure, and it typically appears as a white to off-white powder. Fostamatinib is administered in tablet form and is metabolized in the liver, with its pharmacokinetics influenced by various factors, including food intake. Common side effects may include diarrhea, hypertension, and liver enzyme elevations, necessitating monitoring during treatment. As with any medication, it is essential for patients to discuss potential risks and benefits with their healthcare provider before starting therapy. Overall, Fostamatinib represents a targeted approach in managing autoimmune disorders, showcasing the advancements in pharmacological treatments.

Formula: C₂₃H₂₆FN₆O₉P

InChI: InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)

InChI key: InChIKey=GKDRMWXFWHEQQT-UHFFFAOYSA-N

SMILES: C(OP(=O)(O)O)N1C=2C(OC(C)(C)C1=O)=CC=C(NC3=NC(NC4=CC(OC)=C(OC)C(OC)=C4)=NC=C3F)N2

Synonyms:

• R 788
• 6-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one
• 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-
• Fostamatinib
• RT788
• R7935788
• FOSTAMATINIB (R788);R788
• R788 free base
• R788, >=99%
• R788 5MG
• (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2,3-dihydropyrido[3,2-b][1,4]oxazin-4-yl)methyl dihydrogen phosphate
• R788
• NSC-745942
• FostaMatinib (R788)
• Fostamatinib USP/EP/BP
• CS-883
• [6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate
• R-935788
• R788 (Fostamatinib, FosD, tamatinib fosdium)
• FostaMatinib DisodiuM

FOSTAMATINIB

CAS: 901119-35-5

Formula: C₂₃H₂₆FN₆O₉P

Purity: 98%

Color and Shape: Solid

Molecular weight: 580.4595

Ref: IN-DA00GU5Z

Fostamatinib

CAS: 901119-35-5

Fostamatinib

Purity: ≥90%

Molecular weight: 580.46g/mol

Ref: 54-BUP12486

Fostamatinib

CAS: 901119-35-5

Formula: C₂₃H₂₆FN₆O₉P

Molecular weight: 580.47

Ref: 4Z-F-207001

Fostamatinib

CAS: 901119-35-5

Fostamatinib (R788)(IC50 of 41 nM), which is a prodrug of the active metabolite R406, is a Syk inhibitor. It does not work on Lyn.

Formula: C₂₃H₂₆FN₆O₉P

Purity: 93.08% - 99.38%

Color and Shape: Solid

Molecular weight: 580.46

Ref: TM-T6115

Fostamatinib

Controlled Product

CAS: 901119-35-5

Formula: C₂₃H₂₆FN₆O₉P

Color and Shape: Neat

Molecular weight: 580.47

Ref: TR-F112360

R 788 Sodium Salt Hydrate

Controlled Product

CAS: 901119-35-5

Applications R 788 Sodium Salt Hydrate is a sodium hydrate form of R 788 which is a selective spleen tyrosine kinase (Syk) inhibitor. It may be used in the treatment of autoimmune diseases such as type 1 diabetes and has been tested in the treatment of rheumatoid athritis, leukemia and lymphoma.
References Colonnna, L., et al.: J. Immunol., 185, 1532 (2010); McAdoo, S., et al.: Drug Future, 36, 273 (2011); Efremov, D., et al.: Expert Opin. Inv. Drug., 20, 623 (2011);

Formula: C₂₃H₂₄FN₆Na₂O₉P•x(H₂O)

Color and Shape: Neat

Molecular weight: 624.421801

Ref: TR-R070115

Fostamatinib

CAS: 901119-35-5

Inhibitor of spleen tyrosine kinase SYK; prodrug of R406

Formula: C₂₃H₂₆FN₆O₉P

Purity: Min. 95%

Molecular weight: 580.46 g/mol

Ref: 3D-FF104227